BioCentury
ARTICLE | Company News

NPS sales and marketing update

January 7, 2013 8:00 AM UTC

On Jan. 2, NPS said it set the annual list price for short bowel syndrome (SBS) drug Gattex teduglutide at $295,000. The company, which plans to launch the Orphan drug in February, said it has identified more than 1,000 patients who are eligible for Gattex and expects to have 200-300 patients on the drug by the end of this year. NPS said it "expect[s] payers to provide broad access to Gattex" and now estimates peak revenues will be "well in excess of" its previous estimate of $350 million.

On Dec. 27, 2012, NPS partnered with specialty home infusion providers Accredo Health Group Inc. unit of Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.), BioScrip Inc. (NASDAQ:BIOS, Eden Prairie, Minn.), Coram LLC (Denver, Co.), ThriveRx (Cincinnati, Ohio) and Walgreens Infusion Services (NASDAQ:WAG, Deerfield, Ill.) to distribute Gattex. The providers will also offer clinical and education services to support the use of Gattex. ...